SCHEMBL741255

SCHEMBL741255

CCOc1ccc(-c2ccc3ccccc3n2)c(OCC)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.61
SMN1; SMN2 Q16637 5/20 0.61
LMNA P02545 3/20 0.61
TP53 P04637 1/20 0.61
TLR8 Q9NR97 2/20 0.51
NPC1 O15118 6/20 0.46
MAPT P10636 4/20 0.46
RAB9A P51151 7/20 0.46
ALDH1A1 P00352 4/20 0.46
NFKB1 P19838 1/20 0.46
NFKB2 Q00653 1/20 0.46
RELA Q04206 1/20 0.46
GPBAR1 Q8TDU6 3/20 0.43
CYSLTR1 Q9Y271 2/20 0.43
CYSLTR2 Q9NS75 1/20 0.43
POLB P06746 2/20 0.43
HPGD P15428 2/20 0.43
GAA P10253 1/20 0.43
PARP1 P09874 1/20 0.42
MEN1 O00255 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15361972 0.84 TLR8 (0.54) KDM4ESMN1; SMN2LMNATLR8NPC1
SCHEMBL7005281 0.84 TLR8 (0.49) KDM4ESMN1; SMN2LMNATP53TLR8
SCHEMBL7004489 0.77 PDE10A (0.52) KDM4ESMN1; SMN2TP53TLR8NPC1
SCHEMBL7007754 0.77 NPC1 (0.54) KDM4ESMN1; SMN2LMNATP53TLR8
SCHEMBL28653821 0.77 TLR8 (0.60) KDM4ESMN1; SMN2TLR8NPC1MAPT
SCHEMBL16797438 0.76 KDM4E (1.00) KDM4ESMN1; SMN2LMNATP53NPC1
SCHEMBL14085522 0.74 TP53 (0.49) KDM4ESMN1; SMN2LMNATP53MAPT
SCHEMBL28180362 0.72 MAPT (0.55) KDM4ESMN1; SMN2LMNATP53TLR8
SCHEMBL22033267 0.72 TLR8 (0.56) KDM4ESMN1; SMN2LMNATLR8NPC1
SCHEMBL7005330 0.71 TLR8 (0.51) KDM4ESMN1; SMN2TLR8NPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8138356-B2 Chemical inhibitors of inhibitors of differentiation Angiogeney, Inc. (US) 2012-03-20 US disclosed
US-20090226422-A1 Chemical Inhibitors of Inhibitors of Differentiation ANGIOGENEX 2009-09-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090226422-A1 Chemical Inhibitors of Inhibitors of Differentiation BRAF, MAPK1, RAF1 KDM4E 1876/4885SMN1; SMN2 3141/4885LMNA 2937/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.